- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Levy on Unanswered Questions Regarding the Mechanism of Action of ADCs in NSCLC
February 3rd 2024, 9:35pm
PER® Winter Lung Cancer Conference
Benjamin Levy, MD, discusses the mechanism of action of antibody-drug conjugates in patients with non–small cell lung cancer.
Dr Leal on the Development of DLL3-Targeted Agents in SCLC
February 3rd 2024, 6:20pm
PER® Winter Lung Cancer Conference
Ticiana Leal, MD, discusses the variety of DLL3-targeted agents in development for patients with small cell lung cancer and neuroendocrine tumors.
Dr Pellini on the Development of Increasingly Sensitive ctDNA Assays in NSCLC
February 3rd 2024, 12:55am
PER® Winter Lung Cancer Conference
Bruna Pellini, MD, discusses the importance of developing circulating tumor DNA assays with increased sensitivity.
Dr Rodriguez on the Use of HER2-Directed Therapies in NSCLC
February 3rd 2024, 12:45am
PER® Winter Lung Cancer Conference
Estelamari Rodriguez, MD, MPH, discusses adverse effects associated with HER2-directed antibody-drug conjugates in non–small cell lung cancer.
Dr Salani on the De-Escalation of Therapy in Gynecologic Oncology
January 29th 2024, 9:51pm
Ritu Salani, MD, discusses the de-escalation of therapy and unmet needs within the landscape of gynecologic oncology.
Morphologic Type and Tumor Stage May Inform Real-World Outcomes in RCC
January 28th 2024, 11:00am
Genitourinary Cancers Symposium (ASCO GU)
Real-world recurrence and prognosis was determined through the identification of morphologic RCC types and tumor stages.
Subcutaneous Nivolumab Provides Clinical Equipoise to Standard IV Dosing in ccRCC
January 27th 2024, 9:21pm
Genitourinary Cancers Symposium (ASCO GU)
Subcutaneous nivolumab coformulated with rHuPH20 demonstrated noninferiority of PK exposures vs intravenous nivolumab in metastatic ccRCC.
Dr George on the Efficacy and Safety of Subcutaneous Nivolumab in ccRCC
January 27th 2024, 9:15pm
Genitourinary Cancers Symposium (ASCO GU)
Saby George, MD, FACP, discusses the efficacy and safety of subcutaneous nivolumab in patients with clear cell renal cell carcinoma, according to findings from the phase 3 CheckMate 67T study.
Adjuvant Nivolumab Does Not Provide DFS Advantage in Localized, High-Risk RCC
January 27th 2024, 9:10pm
Genitourinary Cancers Symposium (ASCO GU)
Adjuvant nivolumab monotherapy did not yield a disease-free survival benefit vs placebo in patients with localized renal cell carcinoma.
Adjuvant Pembrolizumab Significantly Prolongs OS vs Placebo in ccRCC
January 27th 2024, 8:57pm
Genitourinary Cancers Symposium (ASCO GU)
Treatment with adjuvant pembrolizumab significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.
Extended Follow-Up Confirm Efficacy of First-Line Pembrolizumab/Lenvatinib Combo in Advanced Non–Clear Cell RCC
January 27th 2024, 7:41pm
Genitourinary Cancers Symposium (ASCO GU)
Frontline pembrolizumab plus lenvatinib continues to show benefit vs historical controls in advanced non–clear cell renal cell carcinoma.
Network Meta-Analysis Sheds Light on Efficacy of Lenvatinib Plus Pembrolizumab Vs SOC in Advanced RCC
January 27th 2024, 7:30pm
Genitourinary Cancers Symposium (ASCO GU)
Lenvatinib/pembrolizumab shows a trend of improved PFS and overall response rate vs standard immunotherapies in advanced renal cell carcinoma.
Belzutifan Improves Symptoms and Extends Time to Treatment Deterioration in Advanced RCC
January 27th 2024, 6:25pm
Genitourinary Cancers Symposium (ASCO GU)
Belzutifan treatment led to improved quality of life outcomes vs treatment with everolimus in patients with advanced renal cell carcinoma.
Adjuvant Pembrolizumab Improves DFS, But Not OS, in Locally Advanced/Muscle-Invasive Urothelial Carcinoma
January 27th 2024, 5:30pm
Genitourinary Cancers Symposium (ASCO GU)
Adjuvant pembrolizumab generated a disease-free survival benefit vs observation in patients with muscle-invasive and locally advanced urothelial carcinoma.
Enfortumab Vedotin Plus Pembrolizumab Maintains Survival Advantage Across Advanced Urothelial Cancer Subgroups
January 27th 2024, 5:13pm
Genitourinary Cancers Symposium (ASCO GU)
Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302.
Onvansertib Induces Preclinical Anti-Tumorigenic Effects in Endometrioid Endometrial Cancer
January 27th 2024, 4:40pm
Nikita Sinha, MD, discusses the effects of onvansertib on cellular proliferation, adhesion, apoptosis, and stress in endometrial cancer cells.
Frontline Pembrolizumab Plus Cabozantinib Elicits Responses in Cisplatin-Ineligible Urothelial Carcinoma
January 27th 2024, 4:20pm
Genitourinary Cancers Symposium (ASCO GU)
Pembrolizumab plus cabozantinib was efficacious in the first-line treatment of patients with cisplatin-ineligible urothelial carcinoma.
Dr Apolo on Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Carcinoma
January 27th 2024, 2:25am
Genitourinary Cancers Symposium (ASCO GU)
Andrea B. Apolo, MD, discusses the AMBASSADOR Alliance A031501 trial of adjuvant pembrolizumab in locally advanced/muscle-invasive urothelial carcinoma.
SGO Winter Meeting Spotlights Key Developments and Debates Across Gynecologic Oncology
January 26th 2024, 10:50pm
Ritu Salani, MD, provides an overview of the variety of sessions presented at the 2024 SGO Winter Meeting.
Urinary MRD Status Potentially Predictive of Recurrence in BCG-Unresponsive NMIBC
January 26th 2024, 10:11pm
Genitourinary Cancers Symposium (ASCO GU)
Assessment of urinary MRD status identified and enabled quantification of molecular responses with nadofaragene firadenovec in BCG-unresponsive NMIBC.